OS
OneStream, Inc. Class A Common Stock
stock NASDAQ

Thanks for sharing the screenshot from the app.
Are you also getting a blank screen when you try to access Fidelity.com? Additionally, have you tried any troubleshooting steps for the app, such as confirming your device is updated to the latest OS and uninstalling and reinstalling the app?
Other steps we typically suggest are switching connections between Wi-Fi and mobile data, shutting the device down for a minute, then turning it back on.

I was looking into this a lot more, and there are a lot of things under the surface, including the company's AI integration for physicians. On top of that, the company and its founder have been around for a long, long time. This isn't something that just sprung up and started trying to sell shares, they've been building networks in Latin America and the middle east for almost 15 years, and it looks like the true fruits of their labor are beginning to show.
People are worried about debt and dilution, but honestly, they've diluted less than 5% of their OS in the last year, and on the OTC that's basically pristine. There's plenty of room for this to move with a low float and more attention, long before the overhanging debt becomes a concern, unless you think they're going to suddenly go under immediately after becoming profitable when it hasn't been an issue for the past years.
I'm adding here, and will continue over the next few months.

Their financials are still garbage (and somehow not even getting better as they start to scale), have no real path to being even GM positive in the next 12 months, and have a ton of debt and shares OS.
A 50% pump off a tiny Google order of 20M thats FOUR YEARS OUT is insane. I sold out a couple weeks ago and am not buying back in.

CAPR I wrote up at $4.20 after the 9-3 negative AdCom and around 80% drop in 3 sessions. I thought FDA would probably say no.
Instead FDA extended the PDUFA to Nov 22 after CAPR submitted another year of HOPE-3 follow up and narrowed the label to upper limb function. Its around $9.40 now. So I had the mechanism right and probability wrong. Being wrong in the direction that pays is still being wrong.
Ran the screen again this weekend. 221 biotechs under $10, 425 catalysts total and 102 inside 90 days.
CAPR $9.40, PDUFA Nov 22
Still watching this one hardest. $544M cap, around $238M cash, 22 months runway. 43% short and huge options interest. But days to cover is only 1.6 so I wouldnt build a squeeze thesis here. The AdCom still voted against the drug. Narrowing the indication doesnt create new data. FDA can still say no.
VNDA $5.43, PDUFA Dec 12
Imsidolimab for generalized pustular psoriasis. GEMINI showed 53% skin clearance by week 4 vs 13% placebo. $328M cap, around $170M liquidity, 14% short. Market clearly doesnt like Vandas history with FDA but the data itself looks interesting.
ANNX $4.87, Phase 3 topline 2H 2026
Probably the biggest binary here. ARCHER II in geographic atrophy. Endpoint is prevention of 15 letter vision loss. If positive this could be the first GA drug to actually show protection of vision instead of only slowing lesion growth.
21% short, around +/-96% implied. Only around 12.5 months runway though.
ESMO confe. Oct 23 to 27
CATX $3.13 is probably my favourite here. Updated Phase 1/2a data, $237M cash vs $357M cap, 33 months runway, 24% short and 18 days to cover.
ZNTL $3.99, I still hold this one. Down from $4.84 when I mentioned it in August.
CMPX $2.38, response rate and PFS looked good but OS was flat. ESMO discussion will probably matter more than the headline here.
KPTI $1.79 Still hasnt worked. I had it at $2.04. $41M cap vs around $65M liquidity. 54% short but only around 7 months runway. Very possible to be right on the drug and still get diluted before getting paid.
BFRI $1.61, PDUFA Sep 28
Ameluz expansion into superficial basal cell carcinoma. Pivotal showed 65.5% clearance vs 4.8%. Looks high probability on paper but its a $21M company with around $5M liquidity. Hard to size comfortably. Probably avoiding MAIA, AGEN, ANVS, ALZN and PCSA mainly because runway is terrible. I do have some OSTX from avg. 1.20ish.
PCSA hurts because 5 officers bought shares on the open market. Strong insider signal but financing risk is stronger for me. Also one reminder on options numbers. Expiry matters a lot. CCCC January options imply around +/-61%, but October options that actually cover the September catalyst imply only around +/-25%.
I also still own a few of these in another broker account from last year, so im not looking at all of them from a completely clean slate.

Mac OS Support

"Excited to see u/fieldai_and Caterpillar advance physical AI across heavy industry." Leveraging NVIDIA accelerated computing, Omniverse technologies. Caterpillar Teamed with NVIDIA to Revolutionize Heavy Industry with Physical AI and Robotics with (QNX 8 OS integrated) Nvidia Jetson Thor Platform.

Disclosure: This is NOT a traditional Graham and Dodd value investment. (No pharma company is) It is an event driven opportunity. Very soon, almost any day, SELLAS will reach data lock on their a phase 3 REGAL trial for AML (Lou Gehrig's Disease) in second complete remission.
The trial enrolled 125 patients. First patient in Feb. 2021- Last in April 2024. End point is overall survival (OS). The trial will data lock when 80 patients have died. On May 11 they announced 78 of the required 80 events have occurred. When 2 more pass away the data will be locked and top line results will be announced, typically anywhere from 3 days to 5 weeks after data lock.
In January of last year SLS announced the results of an interim analysis, conducted after 60 patients had passed away. The result indicated an overall survival of between 12-13.5 months for the analysis cohort, versus 6 months with current std. treatment. That's an encouraging read at 60 deaths. The trial will be successful if the median OS is 12.6 months or higher.
TAM for the indication (AML second complete remission) is estimated to be 9000 patients in the US which is a peak mkt. in the 100's of millions. But what often happens (and most certainly will if this trial is successful) is that if a trial is successful in subgroup population a company will seek a label expansion to reach additional patient populations. The world wide TAM for AML is currently estimated to be between 3.2 and 4.2 billion dollars and expected grow at about a 10% CAGR for the next decade.
In short, SLS is about to reach data lock any day, with top line results releases 3 days to 5 weeks later. With the favorable interim analysis data, it seems reasonable to believe that the trial will reach its endpoint.

I wouldn’t trust a factory reset to scrub data. I would use a dedicated device - an old phone that you keep air-gapped forever. a system that only lives in volatile memory like tails OS or seedsigner is also a safe place to check.

Wait until you find out Google has never charged for the core Andorid OS, which is exactly why there is next to no revenue. 🙄

If you didn't install the OS then it's not your device and it's doing whatever hostile nonsense most benefits whoever actually controls it.
LG is really obviously taking advantage of the spy device that some people decided to buy from them and install in their houses, but other "smart" devices aren't different. And that includes stuff like modern cars that don't even need to be on your network because they have their own cellular modems.

# CSE Option Decision OS is a specialised platform for option trading. It's not a broker platform; as broker we advise to work witk IBKR. That's a fantastic platform, with a Trader Workstation, in which you can build your own fast - buy - and - sell machine. But, as a decision- model before you buy or sell a position, CSE can help you to make the best - possible - decision. It's a unique Fibonacci - based - decision model. In CSE we gave context to the stockchart. We created an algorithm which is capable to help you with the best insights for option trading.

Good idea.
Is there any antyspy OS for TV, that could be flashed on an android TV box?

Settle up first, because I posted a list of these in early August and one of them did something I genuinely did not see coming.
CAPR I wrote it up at $4.20, right after the FDA advisory committee voted 9-3 against deramiocel and the stock had lost about 80% in three sessions. On Aug 24 the company said FDA extended the decision date to Nov 22 rather than ruling in August. They amended the BLA with another year of open label follow up from HOPE-3 and narrowed the ask down to upper limb function, which was the primary endpoint of the pivotal study in the first place. FDA classed it a major amendment, and a major amendment buys three months.
It's around $9.40 now. So I had the mechanism right and the probability wrong, and I want to be blunt that being wrong in the direction that pays is still being wrong. I sized it as a small speculative position because I thought it was going to zero-ish. It wasn't. There was also a guy in the comments last time who told me the AdCom made the August date hopeless and that I'd get people hurt. He was right about the AdCom and wrong about what FDA would do with it, which is roughly where I landed too, just from the other side.
Anyway. Same screen, run again this weekend. 221 biotechs under $10 with a dated catalyst ahead, 425 catalysts total, 102 of them inside 90 days. What's different from August is how bunched up they are. There's a wall between Sep 24 and Nov 22, and a big chunk of the oncology stuff lands in a single week because ESMO is Oct 23 to 27 in Madrid.
**CAPR $9.40, PDUFA Nov 22**
Still the one I'm watching hardest, for completely different reasons than in August.
$544M cap against about $238M cash, 22 months of runway. No gun to their head this time. 43% of the float short on the Aug 14 settlement, 200k+ contracts of open interest which is the deepest chain on this board, December expiry pricing about ±100%.
But days to cover is 1.6. That short is not trapped, volume since August has been enormous. Don't build a squeeze thesis on it. Bear case, and I'd rather say it than have someone say it to me. The AdCom still voted against this drug. A narrowed indication isn't a new trial, it's the same data asking a smaller question, and FDA can still say no. There's an open class action too, Sep 28 lead plaintiff deadline. Analysts are split, one went to Hold on the extension, another to Outperform with a $54 target. Nobody knows.
**VNDA $5.43, PDUFA Dec 12**
Imsidolimab, IL-36R antibody, generalized pustular psoriasis. BLA accepted in February. GEMINI put 53% at skin clearance by week 4 against 13% on placebo, off a single IV dose, published in NEJM Evidence. $328M cap, about $170M liquidity, 15 months. 14% short, ±44%. Third approval in twelve months if it lands.
Why it's still cheap, Vanda picks fights with the FDA in public and the market stopped paying for their pipeline years ago. That's sentiment, not data.
**ANNX $4.87, topline "2H 2026" so any week now**
Biggest binary here, and the window instead of a date is the annoying part.
ARCHER II, Phase 3 vonaprument (used to be ANX007) in geographic atrophy. 630+ patients, 2:1 against sham. The endpoint is the thing: preventing a 15 letter loss, three lines on the chart. Both approved GA drugs slow lesion growth. Neither has shown it protects vision. This would be the first.
21% short, 11 funds adding three quarters straight, two insiders bought on the open market, ±96% implied. The market saying out loud that it has no idea.
12.5 months of runway is the catch. Fine if the data lands. Ugly if it slips.
**ESMO conf. Oct 23 to 27, Madrid**
Three of these headline in the same week.
CATX at $3.13 is my favourite of the three. Bamzireotide navoxetan, alpha emitter in neuroendocrine tumours, updated Phase 1/2a on the 23rd. 76 patients dosed through July. $237M cash against a $357M cap, 33 months, funded through the Phase 3 they're starting around year end. 24% short with 18 days to cover, which is a slow short, unlike CAPR's.
ZNTL at $3.99, rapid oral on DENALI overall survival, azenosertib in platinum resistant ovarian. ORR around 35% in the Cyclin E1 positives. ±75%. I had it at $4.84 in August so it's down 18% and I still hold it.
CMPX at $2.38, oral proffered paper on the full COMPANION-002. Read this one before you get excited. Primary met on response rate, 17.1 vs 5.3. PFS strong, 4.7 vs 2.6 months, HR 0.44. Overall survival 8.9 vs 9.4, HR 1.05, p of 0.78. Flat. Company says 31 control patients crossed over, which is a real confound and also exactly what every company says when OS misses. ESMO is where people who do this for a living get to poke at it in public.
**KPTI $1.79, the one that hasn't worked**
Had it at $2.04. Down 12%, still below its own bank account, $41M cap against about $65M liquidity.
Priority review and accelerated approval requested, and FDA has 60 days just to accept the filing, so the news is Q4. Short interest is 54% of the float now. Was 35%.
7 months of runway. Right on the drug and diluted before you get paid is very much live here.
**One small one**
BFRI at $1.61 has a real PDUFA on Sep 28, Ameluz PDT in superficial basal cell, expanding a drug already approved in actinic keratosis. Pivotal cleared 65.5% against 4.8%. High probability on paper. Also a $21M company with about $5M of liquidity and no chain worth the name, so there's no comfortable way to size it. Completeness, not a pick.
**I may avoid or buy few...**
Under 3 months of cash and I don't care how good the catalyst is.
OSTX, BLA on Sep 30 and basically no runway. MAIA, Phase 3, same. AGEN at $8.24 shows about a month. ANVS has Phase 3 buntanetap and roughly two. ALZN and PCSA both show zero.
PCSA stings, because five insiders bought on the open market and all five were officers. Strongest insider signal on the board. Still won't touch it. A financing at these levels takes more than the conviction gives back.
**Numbers I threw out**
SGMO printed ±608%. It's a ten cent stock, the nearest strike is a huge fraction of the share price, so that's strike spacing, not a forecast. IGC at ±175% is the same thing at thirty cents.
OKUR showed ±8% on fourteen contracts of total open interest. Fourteen. Not a market.
EPRX is still printing 110% of float short, which is not a possible number. Was 103% in August. That field is broken and I've stopped using it.
And then CCCC, which is probably the best example of why expiry selection matters. Short interest is around 38%, and if you look at the January options, they suggest roughly a ±61% move, which looks pretty exciting at first. But the October options, which are the ones that actually cover the September catalyst, are pricing only around ±25%. Same company, same day, but almost a 2.5x difference depending on which expiry you use. If you just grab the January number, you can easily convince yourself the market is expecting some huge September move when the options actually covering the event are telling you something very different. I do have these few in my other broker account from last year avg.

September 6, 2026
SMMT is one I'm researching closely, although I wouldn't call it low-risk.
What caught my attention is the combination of insider ownership, short interest, technical setup and upcoming clinical data.
Co-CEO Robert Duggan directly owned approximately 573.9M shares after purchasing another 3.81M shares at $13.12 on June 12 — roughly a $50M open-market purchase.
The latest published short-interest report showed approximately 37.43M shares short with about 8.69 days to cover as of Aug. 14. That data is delayed, so it shouldn't be treated as the current short position.
More importantly, Summit announced statistically significant overall-survival improvement for ivonescimab vs. pembrolizumab in HARMONi-2 on Sept. 2, while updated global HARMONi OS data are scheduled for WCLC on Sept. 15.
SMMT closed Friday around $17.61 after a strong move. On the 3-month chart, the stock appears to have completed a double-bottom formation and broken above the neckline around $15.40. Holding above that breakout area supports the case for further upside, especially if accompanied by continued strong volume.
Biotech data can obviously move the stock sharply in either direction.

If a laptop compromise was enough to drain your wallet, your private keys were stored on that machine in plaintext or easily extractable form. A hardware wallet keeps keys on a separate chip that never exposes them to the host OS, so even a fully compromised laptop cannot sign transactions. That is the single thing that would have prevented this regardless of how the attacker got in.

**Both Autocare and Alloy Kore partnership with Blackberry's QNX are targeting 3 to 5 times of revenue with full-stack foundation than just foundational OS. But worth noting that both partnerships are also for Functional Safety and Cybersecurity becoming core infrastructure.**
[**https://www.pudn.club/qnx/qnx-and-autocore-build-full-stack-sdv-platform-for-china/**](https://www.pudn.club/qnx/qnx-and-autocore-build-full-stack-sdv-platform-for-china/)
**AI REVIEW**
CrowdStrike endpoint protection list prices range from $59.99 to $184.99 per device per year ($7.99 to $19.99 per month if billed monthly) for its self-serve, tiered packages
Based on CrowdStrike’s standard list pricing ($59.99 to $184.99 per endpoint/year), the expected software revenue per autonomous vehicle ranges from **$60 to $925 per year**, depending entirely on how the manufacturer defines an "endpoint" within the car's architecture.
**It makes sense why Hedge Funds are working so hard for their Master's future revenue? Multiply $60 to $925 per year per car with Average 20M cars per year?**

Just a few..DroneShield (Australia/USA): A dominant player in handheld, mobile, and fixed-site counter-drone hardware (e.g., DroneGun, DroneSentry). They rely heavily on AI-driven RF sensing to detect, identify, and jam drone signals in real time.
Anduril Industries (USA): Known for software-first defense architecture. Their Lattice OS integrates sensor networks, while interceptor assets like Anvil (a kinetic hit-to-kill drone) and Roadrunner / Roadrunner-M (a VTOL, reusable dual-turbojet interceptor) provide automated target neutralisation.
D-Fend Solutions (Israel): Specializes in non-kinetic, non-jamming takeover technology. Their EnforceAir platform uses cyber RF takeover protocols to gain control of rogue drones and force them to safely land in designated zones without causing signal interference to nearby civil aviation or communications.
Epirus (USA): Pioneer in high-power microwave (HPM) technology. Their Leonidas system delivers solid-state directed energy capable of disabling entire swarms of drones simultaneously by frying their internal electronics.
Dedrone (Acquired by Axon) (USA): A global leader in airspace security platforms. Their DedroneTracker.AI uses machine learning across multi-sensor feeds (RF, radar, optical) for autonomous detection and mitigation.
Fortem Technologies (USA): Focuses on radar-guided physical capture. Their DroneHunter F700 is an autonomous interceptor that fires nets to physically capture and tether enemy drones, mitigating collateral damage from falling debris.

Good tool, but it deserves a giant asterisk for anyone finding this thread later: it's great for learning and for testing, and it is not where you generate a seed you intend to actually fund.
If you use it for real, grab the offline release, verify the hash, then run it on a machine with the network physically off (ideally a live OS that never touches your normal drive). And please don't paste an existing seed into it just to "check" something. There is no version of that where your words weren't sitting in the RAM of an online device.
The tool isn't the risk. The tab is.

Was asking why those specific companies rather than drone companies.
If you wanted to diversify I would check out Blackberry, who could very well be the OS for any physical AI. A huge moat to be unleashed imo.